Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell responseResearch in context

Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell responseResearch in context

Summary: Background: Finding the oncogene, which was able to inhibit tumor cells intrinsically and improve the immune answers, will be the future direction for renal cancer combined treatment. Following patient sample analysis and signaling pathway examination, we propose p21-activated kinase 4 (PA...

Full description

Bibliographic Details
Main Authors: Shan Xu, Bohan Ma, Yanlin Jian, Chen Yao, Zixi Wang, Yizeng Fan, Jian Ma, Yule Chen, Xiaoyu Feng, Jiale An, Jiani Chen, Ke Wang, Hongjun Xie, Yang Gao, Lei Li
Format: Article
Language:English
Published: Elsevier 2024-06-01
Series:EBioMedicine
Subjects:
Renal cell carcinoma
PAK4
PROTAC drug
Peptide drug
Immune cell response
Online Access:http://www.sciencedirect.com/science/article/pii/S235239642400197X

Internet

http://www.sciencedirect.com/science/article/pii/S235239642400197X

Similar Items